[Experimental study of a new especially active hypoglycemic sulfonamide, HB-419 or Glibenclamide].
D000818:Animals; D001786:Blood Glucose; D002404:Catheterization; D003981:Diazoxide / Q000037:antagonists & inhibitors; D004285:Dogs; D004357:Drug Synergism; D005260:Female; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects*; D008297:Male; D010477:Perfusion; D051381:Rats; D014044:Tolbutamide / Q000494:pharmacology
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D014044:Tolbutamide; D003981:Diazoxide
Etude expérimentale d'un nouveau sulfamide hypoglycémiant particulièrement actif, le HB 419 ou glibenclamide.